Resistance to activated protein C (APC) is the most prevalent inherited cause of venous thrombosis. The APC resistance phenotype is associated with a single point mutation in the factor V gene, changing Arg' in the APC cleavage site to a Gln. We have investigated 50 Swedish families with inherited APC resistance for this mutation and found it to be present in 47 of them. Perfect cosegregation between a low APC ratio and the presence of mutation was seen in 40 families. In seven families, the co-segregation was not perfect as 12 out of 57 APC-resistant family members were found to lack the mutation. Moreover, in three families with APC resistance, the factor V gene mutation was not found, suggesting another still unidentified cause of inherited APC resistance. Of 308 investigated families members, 146 were normal, 144 heterozygotes, and 18 homozygotes for the factor V gene mutation and there were significant differences in thrombosis-free survival curves between these groups. By age 33 yr, 8% of normals, 20% of heterozygotes, and 40% of homozygotes had had manifestation of venous thrombosis. (J. Clin. Invest. 1994. 94:2521-2524.) Key words: blood coagulation * thrombophilia -protein C * protein S * factor V recently discovered in a single family (2) and is already recognized as a major cause of venous thrombosis (3-6). Intact factor V was found to correct APC resistance (7) which together with close linkage between APC resistance and the factor V gene (8, 9), suggested the molecular defect to be located in the factor V gene. A single point mutation (G to A at position 1691) has been found in many APC-resistant individuals (8) (9) (10) (11) . This mutation predicts replacement of Arg5 in the APC cleavage site of factor Va with a Gln, which results in APCresistant factor Va (8, 12) . The prevalence in the European population of APC resistance is between 3 and 7% (3, 5).
Introduction
Blood coagulation is downregulated by the protein C anticoagulant system ( 1) . Protein C is activated on endothelial cells by thrombin bound to thrombomodulin. Together with its cofactor, protein S, activated protein C (APC)' degrades the activated forms of factors VIII and V (VIlla and Va), whereas intact factors VIII and V are poor substrates for APC.
Inherited APC resistance as a cause of thrombophilia was Patients and controls. Thrombosis patients referred to the Department for Coagulation Disorders, Malmo General Hospital, were investigated for APC resistance, the diagnosis of APC resistance being based on APC ratio s 2.0 in at least two samples drawn on different occasions (3) . APC resistance was judged to be inherited when APC resistance was found in two or more family members. In total, 389 individuals from 50 different families were evaluated for APC resistance. DNA samples were available from 308 family members (179 females and 129 males), including 33 (22 females and 11 males) of the 50 index cases. Table I lists the sizes of the investigated kindreds. The control group, which comprised 125 healthy volunteers, has been described previously (3) .
Methods. Blood sampling and routine laboratory evaluation of coagulation parameters were performed as described (3) . The APC resistance test is a modified activated partial thromboplastin time reaction, in which the anticoagulant response to APC is measured (2, 3) . Results were expressed as APC ratios (clotting time obtained using the APC/CaCl2 solution divided by clotting time obtained with CaCl2). Genomic DNA was prepared from EDTA blood as described (14) . The region in exon 10 that encodes an APC cleavage site in factor V was PCR amplified from genomic DNA using the two primers: 5'GGA ACA ACA CCA (15) . For comparison of two curves, the log rank test, resulting in a test statistic with a chi-squared distribution and one degree of freedom, was used (16) . Laboratory data were expressed as mean±SD. A probability below 0.05 was considered significant.
Results
Laboratory results. The Arg5" to Gin mutation in the factor V gene was found in 47 of the 50 (94%) APC-resistant families. Of 308 family members, 144 were heterozygous, 18 were homozygous, and 146 lacked the mutation. Out of the 33 APC-resistant index cases that were available for genetic analysis, 24 were heterozygous, 5 homozygous, and 4 lacked the mutation. APC resistance cosegregated perfectly with the factor V gene mutation in 40 of the 47 families. In the remaining 7 families, 12 out of 57 APC-resistant individuals lacked the mutation. APC ratios in these 12 individuals ranged from 1.3 to 2.0. APC ratios were low in all homozygous cases, whereas there was an overlap in APC ratios between heterozygotes and normals ( Fig.  1 ). Heterozygotes with a history of thrombosis had significantly lower APC ratios than those without thrombosis (1.5±0.2 vs. 1.8±0.4, P < 0.001), and none of the heterozygotes with APC ratio > 2.0 had had thrombosis. Moreover, relatives without the mutation but with histories of thrombosis had significant lower APC ratios than those without thrombosis, even when protein S-deficient cases were excluded from the analysis (mean±SD of 2.4±0.7 vs. 2.9±0.8, P < 0.05). No influence on APC ratios of age or sex was observed among normal or heterozygous relatives.
The four APC-resistant probands who lacked the mutation had severe thromboembolic disease (deep venous thrombosis, pulmonary emboli, and/or superior sagital sinus thrombosis) but no other known defect. Three of them had only slightly low heterozygotes (n = 142, 1.7±0.3) and homozygotes (n = 16, 1.3±0.2) were highly significant (P < 0.001). Even though the mean value of controls (n = 126, 2.8±0.6) was not different from that of normal relatives, the distribution of values in the two groups appeared different.
However, in a Kalmogorov-Smirnov two-sample test this difference was not significant, P = 0.1.
APC ratios (1.8-2.0), whereas the fourth had an APC ratio of 1.5. DNA samples were available for analysis from several relatives in three of the four families. In one family (five relatives tested), four APC-resistant relatives were found to be heterozygotes for the mutation, even though the index case lacked the mutation. In the remaining two families, slightly low APC ratios (1.8-2.0) were found in several relatives who were negative for the factor V gene mutation; three of eight relatives in one family and one of five in the other. Independent inheritance of protein S deficiency was found in three of the families. 5 protein S-deficient individuals were heterozygous for the factor V mutation, 1 (Table II ). Significant differences in thrombosis-free survival of heterozygotes, homozygotes, and normals were found (Fig. 2) . At 33 yr of age, 8% of those not carrying the mutation, 20% of heterozygotes, and 40% of homozygotes had had at least one manifestation of venous thromboembolic disease. It is noteworthy that also in the group of family members who lacked the mutation, a significant difference in thrombosisfree survival between those with and those without APC resis- We have previously reported a case with severe APC resistance and arterial thrombosis (17) and more data are needed to determine whether APC resistance is associated with an increased risk of arterial thrombosis.
Discussion
The Arg5" to Gln mutation in the factor V gene was found in more than 90% of families with APC resistance and there were significant differences in thrombosis-free survival, as well as in APC ratios, between individuals with and without the mutation, homozygotes being more severely affected than heterozygotes. This demonstrated the factor V mutation to be a risk factor for thrombosis and to be the major cause of APC resistance. In a limited number of individuals with inherited APC resistance, the factor V gene mutation was not found, suggesting that other as yet unknown genetic defects may also cause APC resistance. Such defects appeared to be present also in some families harboring the factor V gene mutation, as the mutation was not found in all APC-resistant family members. The very low APC ratios observed in some heterozygous individuals may be the result of a combination of the putative second genetic defect and the factor V gene mutation. The presence of additional genetic defects associated with slightly low APC response was also suggested by the large group of normal relatives having APC ratios just above the lower normal limit (Fig. 1) . This pattem was not observed in the controls and was not explained by age or sex differences. In this context it is also noteworthy that heterozygous family members with a history of thrombosis had lower APC ratios than those without thrombosis. Even though this is also in line with the hypothesis that these thrombosis-prone families are affected by more than one genetic defect, the possibility of lower APC ratios in thrombotic individuals being a postthrombotic phenomenon cannot be ruled out. (3, 5, 8, 18) . If diagnosis of the factor V mutation in the investigated families were to be based on an APC ratio < 2.0 only, 15% of heterozygotes would not be identified (sensitivity 85%) and 13% of normals would be classified as factor V mutants (specificity 87%). Thus, in families with APC resistance (assuming a 50% prevalence of the factor V gene mutation) the predictive value for the factor V mutation of a positive APC resistance test is 87%, whereas the predictive value of a negative test is 85%. As DNA samples were not available from the control group we do not know whether the nine individuals with APC ratio < 2.0 carry the mutation. In a recent report of a similar reference population, the mutation was found in the 3% of control individuals that had distinct APC resistance, whereas cases with borderline APC ratios were negative for the mutation (8, 18) . In a majority of both heterozygous and homozygous cases, thrombosis was associated with circumstantial risk factors, the most frequent being pregnancy, the use of oral contraceptives, trauma, and surgery, suggesting a combination of circumstantial and genetic risk factors to determine the risk for thrombosis. Heterozygosity for the factor V gene mutation is associated with a 5-10-fold increased risk of thrombosis (8, 18) and unless heterozygous individuals are exposed for circumstantial risk factors, thrombosis may not present until advanced age or not at all. Even though homozygosity is associated with a 50-100-fold increased risk of thrombosis, affected individuals may live healthy lives without thrombosis; the oldest homozygous person in this study being free of thrombosis was 68 yr of age. The relatively mild thrombotic tendency even in homozygous cases is in marked contrast to the severe thrombotic disease that affect individuals with homozygous protein C or protein S deficiency already in the neonatal period ( 19) . In factor Va, several peptide bonds are cleaved by APC and even though the Arg5te to Gln mutation is associated with APC-resistant factor Va, the resistance may not be complete. Moreover, the ability of APC to downregulate the rate of activation of coagulation at the level of factor VIlla is unaffected by the factor V gene mutation.
In conclusion, the APC resistance phenotype is in the majority of cases associated with the same mutation in the factor V gene. Carriers have increased thrombotic risk compared to their normal relatives and homozygotes are the worst affected. In a minority of patients, APC resistance is due to an as yet unknown genetic defect.
